Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 7/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14945812 | 0.87 | FPR2 (0.53) | ATMFPR2 | |
| SCHEMBL14935469 | 0.87 | ATM (0.46) | ALDH1A1ATMFPR2SMN1; SMN2NPSR1 | |
| SCHEMBL14945794 | 0.74 | FPR2 (0.53) | ALDH1A1ATMFPR2SMN1; SMN2TAAR1 | |
| SCHEMBL18044007 | 0.71 | ATM (0.43) | ALDH1A1ATMFPR2CYP1A2GAA | |
| SCHEMBL14945808 | 0.65 | ALDH1A1 (0.36) | ALDH1A1ATMFPR2SMN1; SMN2GAA | |
| SCHEMBL20882772 | 0.65 | ALDH1A1 (0.51) | ALDH1A1ATMFPR2LMNA | |
| SCHEMBL192002 | 0.65 | POLB (0.53) | SMN1; SMN2 | |
| SCHEMBL20882908 | 0.65 | ATM (0.32) | ALDH1A1ATM | |
| SCHEMBL15127244 | 0.64 | AGXT (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL22622393 | 0.63 | FPR2 (0.61) | ALDH1A1ATMFPR2GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492556-B2 | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators | ALLERGAN, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130123215-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123215-A1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | FPR1, FPR2, FPR3 | ALDH1A1 3811/4885ATM 4825/4885FPR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.